US-FED-00000394150 - Notice of Intent to Sole Source: Vaccine Adverse Event Reporting System (VAERS) & Safety Monitoring Support - Deadline September 18,2026

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER)`s Office of Biostatistics and Pharmacovigilance (OPBV)`s Division of Pharmacovigilance (DPV) is responsible for monitoring the safety of vaccines and biologics once they are approved for use under a Biologic Licensing Application (BLA) or authorized for use under an Emergency Use Authorization (EUA).The Contractor shall furnish the necessary services and qualified personnel needed to perform the Statement of Work.